flucytosine has been researched along with Bladder Cancer in 7 studies
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.
flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Murine bladder tumor-2 mouse bladder tumors exposed to intravesically administered RCR vectors exhibited 0%, 9." | 1.34 | Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors. ( Bochner, BH; Cordon-Cardo, C; Kasahara, N; Kikuchi, E; Logg, CR; Menendez, S; Ohori, M; Ozu, C, 2007) |
| " Gene therapy combined with radiation represents a new approach to cancer treatment." | 1.32 | Combination with CD/5-FC gene therapy enhances killing of human bladder-cancer cells by radiation. ( Fujisawa, M; Gotoh, A; Hinata, N; Kamidono, S; Matsumoto, A; Matsuo, M; Okada, H; Shirakawa, T; Zhang, Z, 2003) |
| "LNCaP human prostate cancer cells were co-transfected with these 2 plasmids and luciferase activity was measured to assess promoter activities." | 1.31 | Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system. ( Hayakawa, M; Ikegami, S; Suzuki, S; Tadakuma, T; Yoshimura, I, 2002) |
| "The Ovcar-5 and Skov-3 ovarian cancer cell lines exposed to the Ad-Lp-CD adenoviral vector were much more sensitive to the prodrug 5-fluorocytosine (5FC), which is converted from the 5FC prodrug into the toxic chemical 5-fluorouracil, than was the CCD minimal deviation fibroblast cell line after exposure to the same vector." | 1.31 | The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. ( Crystal, R; Deisseroth, A; Fujii, T; Kacinski, B; Leavitt, J; Peng, XY; Pizzorno, G; Rutherford, T; Sapi, E; Schwartz, P; Won, JH; Zelterman, D, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, L | 1 |
| Zhang, CL | 1 |
| Kang, L | 1 |
| Wang, RF | 1 |
| Yan, P | 1 |
| Zhao, Q | 1 |
| Yin, L | 1 |
| Guo, FQ | 1 |
| Yoshimura, I | 1 |
| Ikegami, S | 1 |
| Suzuki, S | 1 |
| Tadakuma, T | 1 |
| Hayakawa, M | 1 |
| Zhang, Z | 1 |
| Shirakawa, T | 1 |
| Hinata, N | 1 |
| Matsumoto, A | 1 |
| Fujisawa, M | 1 |
| Okada, H | 1 |
| Kamidono, S | 1 |
| Matsuo, M | 1 |
| Gotoh, A | 1 |
| Tan, WL | 1 |
| Xie, Y | 1 |
| Wu, YD | 1 |
| Zhu, WH | 1 |
| Zheng, SB | 1 |
| Shieh, GS | 1 |
| Shiau, AL | 1 |
| Yo, YT | 1 |
| Lin, PR | 1 |
| Chang, CC | 1 |
| Tzai, TS | 1 |
| Wu, CL | 1 |
| Kikuchi, E | 1 |
| Menendez, S | 1 |
| Ozu, C | 1 |
| Ohori, M | 1 |
| Cordon-Cardo, C | 1 |
| Logg, CR | 1 |
| Kasahara, N | 1 |
| Bochner, BH | 1 |
| Peng, XY | 1 |
| Won, JH | 1 |
| Rutherford, T | 1 |
| Fujii, T | 1 |
| Zelterman, D | 1 |
| Pizzorno, G | 1 |
| Sapi, E | 1 |
| Leavitt, J | 1 |
| Kacinski, B | 1 |
| Crystal, R | 1 |
| Schwartz, P | 1 |
| Deisseroth, A | 1 |
7 other studies available for flucytosine and Bladder Cancer
| Article | Year |
|---|---|
Enhanced EJ Cell Killing of (125)I Radiation by Combining with Cytosine Deaminase Gene Therapy Regulated by Synthetic Radio-Responsive Promoter.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Survival; Cyto | 2015 |
Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cytosine Deaminase; Enhancer Elements, Genet | 2002 |
Combination with CD/5-FC gene therapy enhances killing of human bladder-cancer cells by radiation.
Topics: Adenoviridae; Animals; Combined Modality Therapy; Cytosine Deaminase; Dose-Response Relationship, Dr | 2003 |
[Adenovirus-mediated double suicide gene therapy for experimental bladder carcinoma].
Topics: Adenoviridae; Animals; Cell Line; Cell Line, Tumor; Cytosine Deaminase; Defective Viruses; Female; F | 2006 |
Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Combined Modality Therap | 2006 |
Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.
Topics: Administration, Intravesical; Animals; Antimetabolites; Cytosine Deaminase; Female; Flucytosine; Gen | 2007 |
The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
Topics: Adenoviridae; Animals; Cytomegalovirus; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Gene | 2001 |